Results of long-perm iron-chelating therapy

被引:278
作者
Gabutti, V
Piga, A
机构
[1] Paediatric Department, University of Turin
关键词
iron overload; complications; chelation; survival;
D O I
10.1159/000203853
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The improvement in survival and quality of life of iron-overloaded patients achieved by regular subcutaneous chelation has been extensively documented over the years. A review of the long-term results allows one to establish the following points: (1) with regular subcutaneous chelation, a negative iron balance can be obtained in most patients, except very young ones; (2) severe deferoxamine (DFO) toxicity may be prevented by skipping high doses and by carefully monitoring and modulating chelation, especially in patients with a low iron overload; (3) the maintenance of compliance with DFO over 0.6 and of ferritin levels below 2,000 prevents iron overload complications, at least for the first 20 years of life; (4) long-term chelation can reverse functional complications such as liver fibrosis, arrhythmia and echocardiographic abnormalities, but not complications due to extensive tissue alterations, such as frank diabetes, hypothyroidism and myocardiosclerosis; (5) intensive intravenous protocols can be successfully applied in heavily overloaded patients and represent the only possibility to reverse their dangerous iron burden in a relatively short period of time; (6) survival and quality of life in well-chelated patients are approaching a normal pattern, and (7) clinical outcome and prognosis are better evaluated by parameters that consider iron overload and chelation trends.
引用
收藏
页码:26 / 36
页数:11
相关论文
共 108 条
[1]   NONTRANSFERRIN-BOUND SERUM IRON IN THALASSEMIA AND SICKLE-CELL PATIENTS [J].
AHMED, NK ;
HANNA, M ;
WANG, W .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY, 1986, 18 (10) :953-956
[2]  
ALBERA R, 1988, AUDIOLOGY, V172, P1
[3]  
ALDOURI MA, 1990, ACTA HAEMATOL-BASEL, V84, P113
[4]   IRON STATE AND HEPATIC-DISEASE IN PATIENTS WITH THALASSEMIA MAJOR, TREATED WITH LONG-TERM SUBCUTANEOUS DESFERRIOXAMINE [J].
ALDOURI, MA ;
WONKE, B ;
HOFFBRAND, AV ;
FLYNN, DM ;
LAULICHT, M ;
FENTON, LA ;
SCHEUER, PJ ;
KIBBLER, CC ;
ALLWOOD, CA ;
BROWN, D ;
THOMAS, HC .
JOURNAL OF CLINICAL PATHOLOGY, 1987, 40 (11) :1353-1359
[5]  
[Anonymous], THALASSAEMIA TODAY M
[6]   OCULAR CHANGES IN PATIENTS UNDERGOING LONG-TERM DESFERRIOXAMINE TREATMENT [J].
ARDEN, GB ;
WONKE, B ;
KENNEDY, C ;
HUEHNS, ER .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1984, 68 (12) :873-877
[7]  
BAROSI G, 1989, EUR J HAEMATOL, V42, P382
[8]   LONG-TERM CHELATION THERAPY IN THALASSEMIA MAJOR - EFFECT ON LIVER IRON CONCENTRATION, LIVER HISTOLOGY, AND CLINICAL PROGRESS [J].
BARRY, M ;
FLYNN, DM ;
LETSKY, EA ;
RISDON, RA .
BMJ-BRITISH MEDICAL JOURNAL, 1974, 2 (5909) :16-20
[9]   VALUE OF HEPATIC IRON MEASUREMENTS IN EARLY HEMOCHROMATOSIS AND DETERMINATION OF THE CRITICAL IRON LEVEL ASSOCIATED WITH FIBROSIS [J].
BASSETT, ML ;
HALLIDAY, JW ;
POWELL, LW .
HEPATOLOGY, 1986, 6 (01) :24-29
[10]   GROWTH AND SEXUAL-MATURATION IN THALASSEMIA MAJOR [J].
BORGNAPIGNATTI, C ;
DESTEFANO, P ;
ZONTA, L ;
VULLO, C ;
DESANCTIS, V ;
MELEVENDI, C ;
NASELLI, A ;
MASERA, G ;
TERZOLI, S ;
GABUTTI, V ;
PIGA, A .
JOURNAL OF PEDIATRICS, 1985, 106 (01) :150-155